Efficacy and Safety of Modified Rituximab-ESHAP Therapy for Relapsed/Refractory B-Cell Lymphoma

被引：12
作者：
Ueda, K.
Nannya, Y.
Asai, T.
Yamamoto, G.
Hangaishi, A.
Takahashi, T.
Imai, Y.
Kurokawa, M. [1 ,2 ]
机构：
[1] Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, Tokyo 1138655, Japan
[2] Tokyo Univ Hosp, Dept Cell Therapy & Transplantat Med, Tokyo 113, Japan
来源：
JOURNAL OF CHEMOTHERAPY | 2010年 / 22卷 / 01期
关键词：
Rituximab; non-Hodgkin lymphoma; salvage therapy; carboplatin; cisplatin; NON-HODGKINS-LYMPHOMA; SALVAGE CHEMOTHERAPY; RELAPSING LYMPHOMA; CARBOPLATIN; CISPLATIN; ETOPOSIDE; TRIAL; DHAP; CHOP;
D O I：
10.1179/joc.2010.22.1.54
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Combined therapy of rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin (R-ESHAP) has been one of the most frequently used salvage regimens for relapsed/refractory non-Hodgkin's lymphoma. In 2002, we introduced the modified R-ESHAP regimen in which cisplatin was switched to carboplatin. We evaluated the safety and effectiveness of this modified regimen by reviewing the records of 35 patients who had been administered R-ESHAP. Our cohort included 21 patients with diffuse large B cell lymphoma (DLBCL) and 14 patients with follicular lymphoma (FL). The overall response rate (ORR) was 48% for DLBCL and 93% for FL. The overall survival (OS) for patients with DLBCL was 51% with a median follow-up of 11 months, and 91% for patients with FL with a median follow-up of 36 months. Our study indicates that modified R-ESHAP is an effective and safe salvage regimen for relapsed/refractory FL, however, its efficacy for relapsed DLBCL is limited.
引用
收藏
页码：54 / 57
页数：4
相关论文
共 25 条
[1]   Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma [J].
Abali, Hueseyin ;
Ueruen, Yueksel ;
Oeksuezoglu, Berna ;
Budakoglu, Burcln ;
Yildirim, Nuriye ;
Gueler, Tunc ;
Oezet, Guelsuem ;
Zengin, Nurullah .
CANCER INVESTIGATION, 2008, 26 (04) :401-406
[2]  
Bokemeyer C, 1996, ANN ONCOL, V7, P1015
[3]   CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION [J].
CALVERT, AH ;
NEWELL, DR ;
GUMBRELL, LA ;
OREILLY, S ;
BURNELL, M ;
BOXALL, FE ;
SIDDIK, ZH ;
JUDSON, IR ;
GORE, ME ;
WILTSHAW, E .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1748-1756
[4]   Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].
Cheson, BD ;
Horning, SJ ;
Coiffier, B ;
Shipp, MA ;
Fisher, RI ;
Connors, JM ;
Lister, TA ;
Vose, J ;
Grillo-López, A ;
Hagenbeek, A ;
Cabanillas, F ;
Klippensten, D ;
Hiddemann, W ;
Castellino, R ;
Harris, NL ;
Armitage, JO ;
Carter, W ;
Hoppe, R ;
Canellos, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253
[5]   CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].
Coiffier, B ;
Lepage, E ;
Brière, J ;
Herbrecht, R ;
Tilly, H ;
Bouabdallah, R ;
Morel, P ;
Van den Neste, E ;
Salles, G ;
Gaulard, P ;
Reyes, F ;
Gisselbrecht, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242
[6]   CISPLATIN NEPHROTOXICITY - A REVIEW [J].
DAUGAARD, G ;
ABILDGAARD, U .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1989, 25 (01) :1-9
[7]  
*DEVITA CA, 2002, CANC CHEM DRUG MAN
[8]   A sequential Bayesian algorithm for dose individualisation of carboplatin [J].
Duffull, SB ;
Begg, EJ ;
Robinson, BA ;
Deely, JJ .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 39 (04) :317-326
[9]   Clinical pharmacokinetics and dose optimisation of carboplatin [J].
Duffull, SB ;
Robinson, BA .
CLINICAL PHARMACOKINETICS, 1997, 33 (03) :161-183
[10]   Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin [J].
Go, RS ;
Adjei, AA .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :409-422
123